PR Hub

Paloma Pharmaceuticals Inc.

Through first three cohorts of intravitreal macular degeneration Phase I trial, start of National Eye Institute subconjunctival macular degeneration Phase I trial, publication/submission of cancer studies, presentation at AACR 'Targeting PI3K/mTOR Signaling in Cancer' -


JAMAICA PLAIN, Massachusetts, March 1, 2011 - Paloma Pharmaceuticals, Inc.
MORE..

IND Accepted by FDA to Initiate Intravitreal and Subconjunctival Administration of Palomid 529 in Age-Related Macular Degeneration Patients -


JAMAICA PLAIN, Massachusetts, February 4 - Paloma Pharmaceuticals, Inc.
MORE..

Presentation highlights Palomid 529 as a first-in-class dual TORC1/TORC2 inhibitor in Brain Cancer -


JAMAICA PLAIN, Massachusetts, November 16 - Paloma Pharmaceuticals, Inc.
MORE..
Older News
S M T W T F S
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 1 2 3 4 5
Copyright© 2011 The Gaea Times